There have been great strides in the fight against the opioid epidemic since 2018 when Emergent first acquired its flagship product, NARCAN ® Nasal Spray, which is designed to rapidly reverse the ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO ... contract development and manufacturing services for pharmaceutical and biotechnology customers.

Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose ...

Emergent distributes NARCAN Nasal Spray 4 mg, which is the first FDA-approved over-the-counter naloxone product for the emergency treatment of opioid overdose. Under the terms of the six-year ...

EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® (naloxone HCl) Nasal Spray 8 mg in the United ...

GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), a pharmaceutical company with a market capitalization of approximately $510 million, has acquired exclusive commercial rights for KLOXXADO® ...

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

Narcan, a nasal spray that reverses the effects of opioid overdose, will now be available to the public for emergency use at City Hall, Durango Public Library, Durango Community Recreation Center ...

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.